Replies to post #458756 on Anavex Life Sciences Corp (AVXL)

[mrplmer]

PW you might not of listened to the call yesterday.

Normally analyst targets are for a year.

When Missling announced EMA he said the plan would be as ealy as possible in 2024. Yesterday he said by the end of the year more than once.

Remember Jin was on board in Jan of 23.

Yesterday he hinted because of new FDA rules using 1 biomarker, there could be multiple submissions.

Now we know if it takes EMA 7 submission a year then how could they submit to FDA at the same time.

So $15.00 is a annual target and I doubt they get EMA in by December.
I've been an investor for 50 years. I've never seen such malfeasance and lack of transparency in all those years. I might be better off in the lawsuit at $31.50 plus punitive damages if I'm looking at $15.00.

[WilliamMunny]

Power, I would simply say that if he is setting a target price of roughly 3x the current price, he is quite bullish. Most brokerage firms pressure analysts not to post targets more aggressively than that unless there is an immediate catalyst on the horizon. Like yourself, most holders who understand the dynamics here understand that once an MAA has been filed and accepted, AVXL will be trading comfortably above that $15 level. In response to that move, Summit Roy can claim victory and then set a new target of $45 (or whatever). More trades will be generated on the news and the firm's response. That is how the game is played. Even more importantly for holders, once the milestone of filling at the EMA has been reached (and expectations of a similar filing at the FDA gain in credibility), new sell side analysts will step up to the plate and carry the weight of more substantive firms than Jones Trading.